In women with polycystic ovary syndrome (PCOS) and infertility unresponsive to clomiphene citrate, when is laparoscopic ovarian drilling indicated, how is it performed, and what are its risks and success rates?

Laparoscopic Ovarian Drilling in PCOS

Laparoscopic ovarian drilling (LOD) is a second-line surgical treatment for women with clomiphene citrate-resistant PCOS and anovulatory infertility, offering comparable pregnancy rates to gonadotropins while eliminating the risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS).

When LOD is Indicated

LOD should be considered specifically when:

• Clomiphene citrate resistance is documented (failure to ovulate despite adequate CC dosing) 1
• The patient has tubal patency confirmed and no other infertility factors 1
• Male factor infertility has been excluded 1
• The patient wishes to avoid gonadotropin therapy or has concerns about multiple pregnancy/OHSS risk
• Better prognostic factors include: elevated LH >10 IU/L, shorter duration of infertility (<3 years), and absence of tubal disease 2

Treatment Hierarchy per Guidelines

The Endocrine Society guideline establishes this clear sequence 1:

1. First-line: Clomiphene citrate or letrozole for anovulatory infertility
2. Second-line options for CC-resistant patients:
   • Metformin + clomiphene (metformin alone shows higher live birth rates than LOD: RR 1.6,95% CI 1.1-2.5) 1
   • Gonadotropins
   • Laparoscopic ovarian drilling
3. Referral to infertility subspecialist if resistance or failure occurs 1

How LOD is Performed

Surgical Technique

• Unilateral vs bilateral drilling: Evidence shows no significant difference in ovulation rates (81.8% spontaneous ovulation), pregnancy rates (54.5%), or live births between unilateral and bilateral approaches 3, 4, 5
• Unilateral LOD is preferred as it potentially reduces adhesion formation risk while maintaining equivalent efficacy 3, 5
• Standard approach: 4-5 puncture sites per ovary using monopolar diathermy 3, 2
• The procedure is quick and straightforward, though optimal energy dose and number of punctures remain unstandardized 6

Mechanism of Action

LOD works by reducing intraovarian androgen production, rapidly normalizing serum LH and testosterone levels with sustained long-term effects 6. This hormonal correction restores ovulatory function.

Success Rates

Reproductive Outcomes

Recent high-quality evidence from 2026 shows 7:

• LOD pregnancy rate: 18% (lowest among comparators)
• Gonadotropins: 41% (highest)
• Letrozole: 32.8%
• Ovulation rate with LOD: 81.8-93.9% 2
• Cumulative pregnancy rate: 54.5% over extended follow-up 2

Important Caveat

LOD produces significantly fewer oocytes and embryos if IVF is subsequently needed 8. However, pregnancy rates in IVF cycles remain comparable between those with and without prior LOD 8.

Risks and Complications

Major Advantages Over Gonadotropins

• Eliminates multiple pregnancy risk (5% with CC vs near-zero with LOD) 1, 6
• No OHSS risk - this is LOD's most significant safety advantage 7, 8, 6
• More cost-effective and better tolerated than gonadotropin therapy 6

Surgical Risks

Adhesion formation concerns are NOT supported by available data 6. Studies specifically evaluating adhesions found:

• Assessment possible in 36.3% of patients post-operatively
• Zero adhesions found in either unilateral or bilateral groups 3

Premature ovarian failure concerns are also unsupported by current evidence 6, though there are ongoing concerns about long-term ovarian function effects 8.

Pregnancy Complications

Women achieving pregnancy after LOD show increased rates of 2:

• Gestational diabetes mellitus
• Pregnancy-induced hypertension

These require appropriate prenatal monitoring.

Clinical Decision Algorithm

Choose LOD when:

1. CC resistance confirmed (no ovulation despite adequate dosing per FDA label 9)
2. Patient has normal tubes, normal male partner
3. Patient prioritizes avoiding multiple pregnancy/OHSS over maximizing pregnancy rate
4. Favorable prognostic factors present (LH >10 IU/L, infertility <3 years, no tubal disease)

Choose gonadotropins or letrozole when:

1. Maximizing pregnancy rate is the priority (gonadotropins achieve 41% vs LOD's 18%) 7
2. Patient accepts OHSS and multiple pregnancy risks
3. Time to pregnancy is critical

Consider LOD specifically for:

• Patients with prior OHSS history - LOD significantly reduces recurrence risk 8
• Patients desiring long-term menstrual regulation - LOD provides sustained hormonal benefits 7, 6

Key Metabolic Effects

Beyond fertility, LOD produces significant metabolic improvements 7:

• Greater reductions in LH levels
• Decreased anti-Müllerian hormone (AMH)
• Reduced antral follicle count
• More patients achieve menstrual regularity compared to medical therapy

These sustained hormonal changes explain LOD's long-term efficacy despite lower initial pregnancy rates.

Common Pitfalls

• Don't perform LOD without confirming tubal patency and normal male factor - pregnancy rates drop to 23.5% with coexisting tuboperitoneal disease 2
• Don't use LOD as first-line therapy - the Endocrine Society clearly recommends CC/letrozole first 1
• Don't avoid LOD due to adhesion fears - this concern is not evidence-based 6, 3
• Don't expect LOD to match gonadotropin pregnancy rates - accept the trade-off of lower pregnancy rate for elimination of OHSS/multiple pregnancy risk 7